Pandemic Nostalgia: Reduced Social Contact Predicts Consumption of Nostalgic Music During the COVID-19 Pandemic

Some scholars observed a "nostalgia bump” during the COVID-19 pandemic, where people compensated for social isolation by engaging with products and experiences evoking nostalgia. To further explore this effect and its underlying mechanism, the authors tested the hypothesis that reduced social contact during lockdown conditions would lead people to feel lonely and bored and, in turn, increase their consumption of nostalgic music. Study 1 (Nsong = 213,464) established the temporal relationships between social contact and nostalgia by analyzing mobility data and daily listening patterns of top songs on the music platform Spotify from 2019 to 2021. Study 2 (N = 525) was a retrospective survey of individual experiences during the lockdown period. Results showed that reduced social contact had an indirect positive effect on consumption of nostalgic songs through loneliness, but not boredom. These findings shed light on the use of nostalgia as a coping strategy during times of isolation.

Effectiveness of the WHO-Authorized COVID-19 Vaccines: A Rapid Review of Global Reports till 30 June 2021.

Large clinical trials have proven the efficacy of the COVID-19 vaccine, and the number of studies about the effectiveness rapidly grew in the first half of the year after mass vaccination was administrated globally. This rapid review aims to provide evidence syntheses as a means to complement the current evidence on the vaccine effectiveness (VE) against various outcomes in real-world settings. Databases (PubMed, EMBASE, and MedRxiv) were searched up to 30 June 2021, (PROSPERO ID: 266866). A total of 39 studies were included, covering over 15 million participants from 11 nations. Among the general population being fully vaccinated, the VE against symptomatic SARS-CoV-2 infection was estimated at 89-97%, 92% (95% CI, 78-97%), and 94% (95% CI, 86-97%) for BNT162b2, ChAdOx1, and mRNA-1273, respectively. As for the protective effects against B.1.617.2-related symptomatic infection, the VE was 88% (95% CI, 85.3-90.1%) by BNT162b2 and 67.0% (95% CI, 61.3-71.8%) by ChAdOx1 after full vaccination. This review revealed a consistently high effectiveness of certain vaccines among the general population in real-world settings. However, scarce data on the major variants of SARS-CoV-2 and the shortness of the study time may limit the conclusions to the mRNA vaccines and ChAdOx1.